CCR5 antagonists: Host-targeted antivirals for the treatment of HIV infection

Antiviral Chemistry and Chemotherapy

Volumn 16, Issue 6, 2005, Pages 339-354

  Westby, Mike ^a   Van Der Ryst, Elna ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Antiretroviral; Chemokine; Co receptor; Entry; HIV

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; ANTIVIRUS AGENT; APLAVIROC; BMS 043; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PRO 140; RITONAVIR; T 1249; TAK 652; TNX 355; UNCLASSIFIED DRUG; VICRIVIROC;

ABDOMINAL CRAMP; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLATULENCE; GASTROINTESTINAL SYMPTOM; GENE DELETION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; NAUSEA; PATHOGENESIS; PHENOTYPE; PLASMA HALF LIFE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; VIRUS STRAIN;

EID: 28544434492     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020501600601     Document Type: Review

References (102)

1. Adkison KK, Shachoy-Clark A, Fang L, Lou Y, O'Mara K, Berrey MM & Piscitelli SC (2005b) Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. Antimicrobial Agents and Chemotherapy 49:2802-2806.
2. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM & Berger EA (1996) CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958.
3. Arasteh K, Lazzarin A, Clotet B, Lalezari J, Cooper D, Henry K, O'Hearn M, Reynes J, Piliero P, Trottier B, Montaner J, Walmsley S, Nelson M, Katlama C, Chung J, DeMasi R, Guimareas D, Huson L, Donatacci L, Wat C, Kinchelow T, Bertasso A, Miralles GD & Salgo M [2004] TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen. XV International AIDS Conference. Bangkok, Thailand, 11-16 July 2004. Abstract MoOrB1058. Medscape General Medicine 6:MoOrB1058.
4. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K & Fujino M (1999) A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proceedings of the National Academy of Sciences of the USA 96:5698-5703.
5. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J & Weiss RA (1998) A new classification for HIV-1. Nature 391:240.
6. Berger EA, Murphy PM & Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annual Review of Immunology 17:657-700.
7. Blanpain C, Doranz BJ, Bondue A, Govaerts C, De Leener A, Vassart G, Doms RW, Proudfoot A & Parmentier M (2003) The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. Journal of Biological Chemistry 278:5179-5187.
8. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. Journal of Experimental Medicine 200:749-759.
9. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, Asselin JJ, Cheung PK, Hogg RS, Montaner JS & Harrigan PR (2005) Molecular and clinical epidemiology of CXCR4 - using HIV-1 in a large population of antiretroviral-naive individuals. Journal of Infectious Diseases 192:466-474.
10. Carr A (2003) Toxicity of antiretroviral therapy and implications for drug development. Nature Reviews Drug Discovery 2:624-634.
11. Castonguay LA, Weng Y, Adolfsen W, Di Salvo J, Kilburn R, Caldwell CG, Daugherty BL, Finke PE, Hale JJ, Lynch CL, Mills SG, MacCoss M, Springer MS & DeMartino JA (2003) Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry 42:1544-1550.
12. Chan DC & Kim PS (1998) HIV entry and its inhibition. Cell 93:681-684.
13. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C & Sodroski J (1996) The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
14. Clotet B, Raffi F, Cooper D, Delfraissy JF, Lazzarin A, Moyle G, Rockstroh J, Soriano V & Schapiro J (2004) Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 18:1137-1146.
15. Coakley E, Petropoulos CJ & Whitcomb JM (2005) Assessing chemokine co-receptor usage in HIV. Current Opinion in Infectious Diseases 18:9-15.
16. + T cells. Science 270:1811-1815.
17. d'Arminio MA, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U & Moroni M (2000) Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 14:499-507.
18. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R & O'Brien SJ (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273:1856-1862.
19. Delobel P, Sandres-Saune K, Cazabat M, Pasquier C, Marchou B, Massip P & Izopet J (2005) R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 38:382-392.
20. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR & Landau NR (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
21. Dorn CP, Finke PE, Oates B, Budhu RJ, Mills SG, MacCoss M, Malkowitz L, Springer MS, Daugherty BL, Gould SL, DeMartino JA, Siciliano SJ, Carella A, Carver G, Holmes K, Danzeisen R, Hazuda D, Kessler J, Lineberger J, Miller M, Schleif WA & Emini EA (2001) Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes. Bioorganic and Medicinal Chemistry Letters 11:259-264.
22. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
23. Dragic T, Trkola A, Lin SW, Nagashima KA, Kajumo F, Zhao L, Olson WC, Wu L, Mackay CR, Allaway GP, Sakmar TP, Moore JP & Maddon PJ (1998) Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. Journal of Virology 72:279-285.
24. Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, Spence R & Miralles GD (2004) Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. Journal of Infectious Diseases 189:1075-1083.
25. Este JA (2002) Sch-351125 and Sch-350634. Schering-Plough. Current Opinion in Investigational Drugs 3:379-383.
26. Este JA, De Vreese K, Witvrouw M, Schmit JC, Vandamme AM, Anne J, Desmyter J, Henson GW, Bridger G & De Clercq E (1996) Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Antiviral Research 29:297-307.
27. Farzan M, Choe H, Vaca L, Martin K, Sun Y, Desjardins E, Ruffing N, Wu L, Wyatt R, Gerard N, Gerard C & Sodroski J (1998) A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. Journal of Virology 72:1160-1164.
28. Farzan M, Chung S, Li W, Vasilieva N, Wright PL, Schnitzler CE, Marchione RJ, Gerard C, Gerard NP, Sodroski J & Choe H (2002) Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region. Journal of Biological Chemistry 277:40397-40402.
29. Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard NP, Gerard C, Sodroski J & Choe H (1999) Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96:667-676.
30. Farzan M, Vasilieva N, Schnitzler CE, Chung S, Robinson J, Gerard NP, Gerard C, Choe H & Sodroski J (2000) A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. Journal of Biological Chemistry 275:33516-33521.
31. Fätkenheuer G, Pozniak A, Johnson M, Plettenberg A, Staszewski S, Hoepelman IM, Saag M, Goebel F, Rockstroh J, Dezube B, Jenkins T, Medhurst C, Sullivan J, Ridgway C, Abel S, James I, Youle M & Van der Ryst E [2004] Evaluation of dosing frequency and food effect on viral load reduction during short-term monotherapy with UK-427,857 a novel CCR5 antagonist. XV International AIDS Conference. Bangkok, Thailand, 11-16 July 2004. Abstract TuPeB4489. Medscape General Medicine 6:TuPeB4489.
32. Feng Y, Broder CC, Kennedy PE & Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877.
33. Fitzgibbon JE, Gaur S, Gavai M, Gregory P, Frenkel LD & John JF, Jr. (1998) Effect of the HIV-1 syncytium-inducing phenotype on disease stage in vertically-infected children. Journal of Medical Virology 55:56-63.
34. Garred P, Eugen-Olsen J, Iversen AK, Benfield TL, Svejgaard A & Hofmann B (1997) Dual effect of CCR5 delta 32 gene deletion in HIV-1-infected patients. Copenhagen AIDS Study Group. Lancet 349:1884.
35. Griffin S (2003) Structure and organization of HIV. In Human Immunodeficiency Virus; pp. 2:1-2:23. Edited by DD Richman. London: International Medical Press.
36. Gudermann T, Nurnberg B & Schultz G (1995) Receptors and G proteins as primary components of transmembrane signal transduction. Part 1. G-protein-coupled receptors: structure and function. Journal of Molecular Medicine 73:51-63.
37. Gurrath M (2001) Peptide-binding G protein-coupled receptors: new opportunities for drug design. Current Medicinal Chemistry 8:1605-1648.
38. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, Jackson JB, Coombs RW, Glesby MJ, Flexner CW, Bridger GJ, Badel K, Macfarland RT, Henson GW & Calandra G (2004) Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes 37:1253-1262.
39. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD & Koup RA (1996) The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Medicine 2:1240-1243.
40. Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, Ketas TJ, Trkola A, Klotman ME, Maddon PJ, Olson WC & Israel RJ (2000) Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. Journal of Infectious Diseases 182:326-329.
41. Jensen MA, Li FS, 't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB & Mullins JI (2003) Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. Journal of Virology 77:13376-13388.
42. Jiang S, Lu H, Liu S, Zhao Q, He Y & Debnath AK (2004) N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrobial Agents and Chemotherapy 48:4349-4359.
43. Kitrinos K, LaBranche C, Stanhope M, Madsen H & Demarest J (2005) Clonal analysis detects pre-existing R5X4-tropic virus in patient demonstrating population-level tropism shift on 873140 monotherapy. Antiviral Therapy 10:S68.
44. Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA, Korber BT, Wolinsky SM & Moore JP (2004) Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. Journal of Virology 78:2790-2807.
45. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, Reimann KA, Larson JL, Yarbough PO, Curt V & Shanahan WR, Jr. (2004) Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. Journal of Infectious Diseases 189:286-291.
46. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J & Hendrickson WA (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
47. Lalezari JP, Bellos NC, Sathasivam K, Richmond GJ, Cohen CJ, Myers RA, Jr., Henry DH, Raskino C, Melby T, Murchison H, Zhang Y, Spence R, Greenberg ML, Demasi RA & Miralles GD (2005) T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. Journal of Infectious Diseases 191:1155-1163.
48. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Jr., Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J & Salgo M (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. New England Journal of Medicine 348:2175-2185.
49. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C & Salgo M (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. New England Journal of Medicine 348:2186-2195.
50. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, Parmentier M, Chang CN, Price K, Tsang M & Doms RW (1999) Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. Journal of Biological Chemistry 274:9617-9626.
51. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, Gong YF, Wang HG, Rose R, Yamanaka G, Robinson B, Li CB, Fridell R, Deminie C, Demers G, Yang Z, Zadjura L, Meanwell N & Colonno R (2003) A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proceedings of the National Academy of Sciences of the USA 100:11013-11018.
52. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA & Landau NR (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377.
53. Madani N, Perdigoto AL, Srinivasan K, Cox JM, Chruma JJ, LaLonde J, Head M, Smith AB, III & Sodroski JG (2004) Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. Journal of Virology 78:3742-3752.
54. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA & Axel R (1986) The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47:333-348.
55. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y & Mitsuya H (2004) Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. Journal of Virology 78:8654-8662.
56. Maeda Y, Foda M, Matsushita S & Harada S (2000) Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1 alpha. Journal of Virology 74:1787-1793.
57. Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, Baroudy BM, Strizki J & Moore JP (2005) Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338:182-199.
58. Martin-Carbonero L (2004) Discontinuation of the clinical development of fusion inhibitor T-1249. AIDS Reviews 6:61.
59. Martinez-Picado J, DePasquale MP, Kartsonis N, Hanna GJ, Wong J, Finzi D, Rosenberg E, Gunthard HF, Sutton L, Savara A, Petropoulos CJ, Hellmann N, Walker BD, Richman DD, Siliciano R & D'Aquila RT (2000) Antiretroviral resistance during successful therapy of HIV type 1 infection. Proceedings of the National Academy of Sciences of the USA 97:10948-10953.
60. Moore JP, Kitchen SG, Pugach P & Zack JA (2004) The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Research and Human Retroviruses 20:111-126.
61. Mosier DE, Picchio GR, Gulizia RJ, Sabbe R, Poignard P, Picard L, Offord RE, Thompson DA & Wilken J (1999) Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. Journal of Virology 73:3544-3550.
62. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J & Gazzard BG (2005) Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. Journal of Infectious Diseases 191:866-872.
63. Mueller A & Strange PG (2004) The chemokine receptor, CCR5. International Journal of Biochemistry and Cell Biology 36:35-38.
64. Muro E, Droste JA, Hofstede HT, Bosch M, Dolmans W & Burger DM (2005) Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. Journal of Acquired Immune Deficiency Syndromes 39:419-421.
65. Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, Ito M, Koyanagi Y & Mitsuya H (2005) Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. Journal of Virology 79:2087-2096.
66. Nelson JA, Fiscus SA & Swanstrom R (1997) Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay. Journal of Virology 71:8750-8758.
67. Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Guo Y, Moore JP, Maddon PJ & Dragic T (1999) Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. Journal of Virology 73:4145-4155.
68. Ostrowski MA, Justement SJ, Catanzaro A, Hallahan CA, Ehler LA, Mizell SB, Kumar PN, Mican JA, Chun TW & Fauci AS (1998) Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. Journal of Immunology 161:3195-3201.
69. Pastore C, Ramos A & Mosier DE (2004) Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. Journal of Virology 78:7565-7574.
70. Philpott SM (2003) HIV-1 coreceptor usage, transmission, and disease progression. Current HIV Research 1:217-227.
71. Pierson TC, Doms RW & Pohlmann S (2004) Prospects of HIV-1 entry inhibitors as novel therapeutics. Reviews in Medical Virology 14:255-270.
72. Platt EJ, Durnin JP & Kabat D (2005) Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. Journal of Virology 79:4347-4356.
73. Princen K, Hatse S, Vermeire K, Aquaro S, De Clercq E, Gerlach LO, Rosenkilde M, Schwartz TW, Skerlj R, Bridger G & Schols D (2004) Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. Journal of Virology 78:12996-13006.
74. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF & Bozzette SA (2004) The prevalence of antiretroviral drug resistance in the United States. AIDS 18:1393-1401.
75. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA & Sodroski J (1998) A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280:1949-1953.
76. Roda Husman AM, van Rij RP, Blaak H, Broersen S & Schuitemaker H (1999) Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. Journal of Infectious Diseases 180:1106-1115.
77. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G & Parmentier M (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725.
78. Schuitemaker H, Kootstra NA, de Goede RE, de Wolf F, Miedema F & Tersmette M (1991) Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. Journal of Virology 65:356-363.
79. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL & Mullins JI (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. Journal of Virology 73:10489-10502.
80. Shen DM, Shu M, Mills SG, Chapman KT, Malkowitz L, Springer MS, Gould SL, DeMartino JA, Siciliano SJ, Kwei GY, Carella A, Carver G, Holmes K, Schleif WA, Danzeisen R, Hazuda D, Kessler J, Lineberger J, Miller MD & Emini EA (2004) Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains. Bioorganic and Medicinal Chemistry Letters 14:935-939.
81. Sista P, Melby T, Dhingra U, Cammack N, McKenna P, Dehertogh P & Matthews T (2001) The fusion inhibitors T-20 and T-1249 demonstrate potent in vitro antiviral activity against clade B HIV-1 isolates resistant to reverse transcriptase and protease inhibitors and non-B clades. Antiviral Therapy 6:3.
82. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, Endres M, Palani A, Shapiro S, Clader JW, Greenlee WJ, Tagat JR, McCombie S, Cox K, Fawzi AB, Chou CC, Pugliese-Sivo C, Davies L, Moreno ME, Ho DD, Trkola A, Stoddart CA, Moore JP, Reyes GR & Baroudy BM (2001) SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proceedings of the National Academy of Sciences of the USA 98:12718-12723.
83. Tagat JR, McCombie SW, Nazareno D, Labroli MA, Xiao Y, Steensma RW, Strizki JM, Baroudy BM, Cox K, Lachowicz J, Varty G & Watkins R (2004) Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4- (trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperaz inyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. Journal of Medicinal Chemistry 47:2405-2408.
84. Takashima K, Miyake H, Furuta RA, Fujisawa JI, Iizawa Y, Kanzaki N, Shiraishi M, Okonogi K & Baba M (2001) Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication. Antimicrobial Agents and Chemotherapy 45:3538-3543.
85. Thelen M (2001) Dancing to the tune of chemokines. Nature Immunology 2:129-134.
86. + T-cell lines from normal donors by human immunodeficiency virus type 1 isolates with non-syncytium-inducing genotype and phenotype in MT-2 cells. Journal of Virology 69:7099-7105.
87. Tremblay CL, Giguel F, Kollmann C, Guan Y, Chou TC, Baroudy BM & Hirsch MS (2002) Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrobial Agents and Chemotherapy 46:1336-1339.
88. Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ & Olson WC (2001) Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. Journal of Virology 75:579-588.
89. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani A, Shapiro S, Clader JW, McCombie S, Reyes GR, Baroudy BM & Moore JP (2002) HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proceedings of the National Academy of Sciences of the USA 99:395-400.
90. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, McCombie S, Baroudy B, Moore JP, Sakmar TP & Dragic T (2003) Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. Journal of Virology 77:5201-5208.
91. Tuttle DL, Anders CB, Aquino-De Jesus MJ, Poole PP, Lamers SL, Briggs DR, Pomeroy SM, Alexander L, Peden KW, Andiman WA, Sleasman JW & Goodenow MM (2002) Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. AIDS Research and Human Retroviruses 18:353-362.
92. + T cell depletion and viral replication in SIV infection. Science 280:427-431.
93. Veazey RS, Klasse PJ, Ketas TJ, Reeves JD, Piatak M, Jr., Kunstman K, Kuhmann SE, Marx PA, Lifson JD, Dufour J, Mefford M, Pandrea I, Wolinsky SM, Doms RW, DeMartino JA, Siciliano SJ, Lyons K, Springer MS & Moore JP (2003) Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. Journal of Experimental Medicine 198:1551-1562.
94. Watson C, Jenkinson S, Kazmierski W & Kenakin T (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Molecular Pharmacology 67:1268-1282.
95. Westby M, Napier C, Mansfield R, Collins D, Huang W, Hellmann N, Lie Y & Perros M (2003) Sensitivity of Env-gene recombinant viruses derived from antiretroviral drug-sensitive and -resistant HIV-1 clinical isolates to the novel CCR5 antagonist, UK-427,857. XII International HIV Drug Resistance Workshop. Los Cabos, Mexico, 10-14 June 2003. Abstract 23. Antiviral Therapy 8:S26
96. WHO (2004) AIDS epidemic update, December 2004. Edited by UNAIDS/WHO 2004 Joint United Nations Programme on HIV/AIDS (UNAIDS) World Health Organisation (WHO) UNAIDS/04.45E (English original, December 2004) ISBN 92 9173 390 3.
97. Willoughby CA, Berk SC, Rosauer KG, Degrado S, Chapman KT, Gould SL, Springer MS, Malkowitz L, Schleif WA, Hazuda D, Miller M, Kessler J, Danzeisen R, Holmes K, Lineberger J, Carella A, Carver G & Emini EA (2001) Combinatorial synthesis of CCR5 antagonists. Bioorganic and Medicinal Chemistry Letters 11:3137-3141.
98. Wolinsky SM, Veazey RS, Kunstman KJ, Klasse PJ, Dufour J, Marozsan AJ, Springer MS & Moore JP (2004) Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology 328:19-29.
99. Wood A & Armour D (2005) The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Progress in Medicinal Chemistry 43:239-271.
100. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, Choe H, Sodroski J, Newman W, Koup RA & Mackay CR (1997) CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. Journal of Experimental Medicine 185:1681-1691.
101. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA & Sodroski JG (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711.
102. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA & Ho DD (1993) Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179-1181.